Shire reported a strong quarter with Vyvanse, HAE portfolio (Cinryze and Firazyr) and GI (Lialda, Gattex and Natpara) driving the 12% CER product revenue growth (all revenue growth numbers at CER unless specified) to $1.6bn, pretty much in line with our expectations. Total revenue was up 13% to $1.7bn during the quarter. For the full year, product sales grew by 9% to $6.1bn, with double-digit growth by Vyvanse (+21%), Lialda (+10%), Cinryze (+24%) and Firazyr (+25%); growth in the US was pred
11 Mar 2016
Strong Q4 but biotech and Baxalta angles continue to weigh
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q4 but biotech and Baxalta angles continue to weigh
Shires Income PLC GBP (SHRS:LON) | 222 5.5 1.1% | Mkt Cap: 91.8m
- Published:
11 Mar 2016 -
Author:
Kamla Singh -
Pages:
3
Shire reported a strong quarter with Vyvanse, HAE portfolio (Cinryze and Firazyr) and GI (Lialda, Gattex and Natpara) driving the 12% CER product revenue growth (all revenue growth numbers at CER unless specified) to $1.6bn, pretty much in line with our expectations. Total revenue was up 13% to $1.7bn during the quarter. For the full year, product sales grew by 9% to $6.1bn, with double-digit growth by Vyvanse (+21%), Lialda (+10%), Cinryze (+24%) and Firazyr (+25%); growth in the US was pred